In a systemic NPM-ALK+ T cell lymphoma mouse model, combined treatment with ASP3026 and PPP was associated with slower tumor growth and longer survival when compared with individual drug treatments. Here, ALK is linked to T-cell non-Hodgkin lymphoma.